Jasper Therapeutics Inc. (JSPRW)
NASDAQ: JSPRW
· Real-Time Price · USD
0.09
-0.01 (-14.29%)
At close: Jun 09, 2025, 3:57 PM
Jasper Therapeutics Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 1.17M | n/a | n/a | n/a | 2.05M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 587K | n/a | 299K | 288K | 283K | 276K | 377K | 373K | 367K | 358K | 313K | 272K | 230K | 336K | n/a | n/a |
Gross Profit | n/a | 587K | n/a | -299K | -288K | 1.77M | -276K | -377K | -373K | -367K | -358K | -313K | -272K | -230K | -336K | n/a | n/a |
Operating Income | -21.8M | -25.29M | -19.89M | -15.99M | -15.07M | -17.73M | -19.36M | -17.83M | -13.95M | -13.75M | -12.71M | -11.96M | -12.78M | -12.08M | -10.08M | -8.42M | -6.25M |
Interest Income | 624K | 938K | 1.28M | 1.45M | 1.39M | 1.23M | 1.43M | 1.44M | 1.1M | n/a | 268K | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | n/a | 46.95M | -18.64M | -14.58M | -13.73M | -16.58M | -17.54M | -16.08M | -14.26M | -13.21M | -11.86M | -10.4M | -2.21M | -9.06M | -3.41M | -8.41M | -9.75M |
Net Income | n/a | 46.95M | -18.64M | -14.58M | -13.73M | -16.58M | -17.54M | -16.08M | -15.91M | -12.68M | -10.75M | -8.85M | 8.36M | -9.06M | -3.41M | -8.41M | -9.75M |
Selling & General & Admin | 5.64M | 5.8M | 5.43M | 4.7M | 4.49M | 3.61M | 4.51M | 4.53M | 4.14M | 4.46M | 3.69M | 3.83M | 4.59M | 3.42M | 2.89M | 3.26M | 1.83M |
Research & Development | 16.16M | 19.77M | 14.46M | 11.3M | 10.3M | 13.84M | 14.85M | 13.3M | 9.8M | 9.28M | 9.02M | 8.13M | 8.19M | 8.66M | 7.19M | 5.16M | 4.42M |
Other Expenses | n/a | 62K | n/a | -40K | -22K | -118K | 51K | -109K | -70K | 301K | n/a | 89K | -72K | n/a | n/a | 4K | 1K |
Operating Expenses | 21.8M | 25.57M | 19.89M | 15.99M | 14.78M | 17.44M | 19.36M | 17.83M | 13.95M | 13.75M | 12.71M | 11.96M | 12.78M | 12.08M | 10.08M | 8.42M | 6.25M |
Interest Expense | n/a | 5.06M | n/a | n/a | n/a | n/a | n/a | n/a | 313K | n/a | 268K | n/a | n/a | n/a | 9K | n/a | 3.5M |
Selling & Marketing Expenses | n/a | 288K | n/a | n/a | -288K | -283K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 26.16M | 19.89M | 15.99M | 15.07M | 17.73M | 19.36M | 17.83M | 13.95M | 13.75M | 12.71M | 11.96M | 12.78M | 12.08M | 10.08M | 8.42M | 6.25M |
Income Tax Expense | n/a | 54.28K | n/a | -299K | 244.72K | 1.91M | -1.71M | -1.86M | 1.65M | -536K | -1.11M | -1.56M | -10.57M | -9.3M | -132K | -4K | 7M |
Shares Outstanding (Basic) | 14.58M | 14.58M | 15M | 14.99M | 13.33M | 11.04M | 10.97M | 10.92M | 8.82M | 3.67M | 36.57M | 36.4M | 36.31M | 4.97M | 4.97M | 37.82M | 37.82M |
Shares Outstanding (Diluted) | 14.58M | 14.58M | 15M | 14.99M | 13.33M | 11.04M | 10.97M | 10.92M | 8.82M | 3.67M | 36.57M | 36.4M | 36.31M | 4.97M | 4.97M | 37.82M | 37.82M |
EPS (Basic) | -1.41 | 3.22 | -1.24 | -0.97 | -1.03 | -1.5 | -1.6 | -1.47 | -1.8 | -3.46 | -0.29 | -0.24 | 0.23 | -1.82 | -0.69 | -0.22 | -0.26 |
EPS (Diluted) | -1.41 | 3.22 | -1.24 | -0.97 | -1.03 | -1.5 | -1.6 | -1.47 | -1.8 | -3.46 | -0.29 | -0.24 | 0.23 | -1.82 | -0.69 | -0.22 | -0.26 |
EBITDA | -21.8M | 45.87M | -19.35M | -15.69M | -14.78M | -17.44M | -19.09M | -17.55M | -13.67M | -13.47M | -12.44M | -11.74M | -12.56M | -11.89M | -3.07M | -8.39M | -6.23M |
EBIT | n/a | 50.95M | -19.89M | -15.99M | -15.07M | -17.73M | -19.36M | -17.83M | -13.95M | -13.75M | -12.71M | -11.96M | -12.78M | -15.26M | -3.4M | -8.42M | -6.25M |
Depreciation & Amortization | n/a | -1.13M | 541K | 299K | 288K | 283K | 276K | 377K | 373K | 367K | 358K | 313K | 272K | 230K | 336K | 29K | 22K |